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Schizophrenia is associated with a substantially increased somatic morbidity and mortality, which may
partly be caused by accelerated cellular aging. Oxidative stress is an established mediator of aging and a
suggested aetiological mechanism in both schizophrenia and age-related medical disorders such as
cardiovascular disease, type 2 diabetes and dementia. We determined the urinary excretion of markers
of systemic Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) oxidation, 8-oxo-7,8-dihydro-
20-deoxyguanosine and 8-oxo-7,8-dihydroguanosine, respectively, in 40 schizophrenia patients and
40 age- and sex-matched controls, using ultra-performance liquid chromatography with tandem mass
spectrometry. Measures of psychopathology, perceived stress and cortisol secretion were collected.
Patients were re-examined after four months. We found a 20% increase in the median excretion of
both markers in schizophrenia patients vs. healthy controls (P¼0.003 and o0.001, respectively). This
difference persisted after the adjustment for multiple demographical, lifestyle and metabolic factors.
In patients, the marker excretion was not inﬂuenced by medication load, and was not driven by
symptom severity, perceived stress or cortisol secretion, neither at baseline nor in relation to changes at
follow-up. We conclude that schizophrenia is associated with increased systemic nucleic acid damage
from oxidation, which could constitute a molecular link between schizophrenia and its associated signs
of accelerated aging.
& 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Schizophrenia has been suggested to constitute a ‘‘syndrome
of accelerated aging’’ (Kirkpatrick et al., 2008). Life expectancy is
shortened with as much as 15–20 years, mainly due to increased
mortality from cardiovascular disease (Hoang et al., 2011;
Wahlbeck et al., 2011). Furthermore, schizophrenia is associated
with mildly accelerated cognitive decline across the lifespan,
paralleled by structural brain alterations such as ventricular
enlargement and hippocampal volume reduction (Jeste et al.,
2011; Shenton et al., 2001; Velakoulis et al., 2006). Finally, some
studies have found telomere length, a molecular correlate of
aging, to be reduced in schizophrenia patients in comparison tod Ltd. All rights reserved.
enhagen, University Hospital
100 Copenhagen, Denmark.
(A. Jorgensen).healthy controls (Kao et al., 2008), although others have found no
difference (Mansour et al., 2011).
Recent evidence has converged on mitochondrial dysfunction
and oxidative stress as potential pathogenetic mechanisms in
schizophrenia, with ﬁndings of both cerebral and peripheral
perturbations in these systems (Arvindakshan et al., 2003b;
Gysin et al., 2007; Kunz et al., 2008; Prabakaran et al., 2004;
Regenold et al., 2009; Rosenfeld et al., 2011), as well as beneﬁcial
clinical effects of antioxidant therapy (Arvindakshan et al., 2003a;
Chengappa et al., 2012; Dakhale et al., 2005). Similarly, adminis-
tration of N-acetyl cystein (NAC) – a precursor of the key brain
antioxidant glutathione – lead to improvement of clinical symp-
toms and auditory sensory processing in schizophrenia (Berk
et al., 2008; Lavoie et al., 2007). Interestingly, preclinical experi-
ments have indicated that glutathione deﬁcits produce neuroa-
natomical and cognitive deﬁcits similar to those observed in
schizophrenia, and that these effects are counteracted by NAC
administration (Cabungcal et al., 2012; Choy et al., 2010).
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cleic Acid (DNA) and Ribonucleic Acid (RNA) is suspected to play a
critical role in cellular aging (Finkel and Holbrook, 2000), as well
as in the development of age-related conditions such as type 2
diabetes, cardiovascular disease and neurodegeneration (Bossy-
Wetzel et al., 2004; Broedbaek et al., 2011; Harrison et al., 2003;
Nunomura et al., 2009). Genotoxic stress from oxidation activate
DNA damage signalling pathways and accelerates telomere ero-
sion, thereby increasing the risk of cellular senescence or apop-
tosis, which are known to be key events in the aging process
(Sahin and DePinho, 2010). Hence, a chronic state of increased
oxidative stress on nucleic acids could perhaps underlie the
association between schizophrenia, cognitive decline and age-
associated morbidity. In that context, a recent study provided
compelling evidence that mitochondrial dysfunction and oxida-
tive stress may be speciﬁcally involved in the cognitive deﬁcit
endophenotype of schizophrenia (Jablensky et al., 2012).
Urinary 8-oxo-7,8-dihydro-20-deoxyguanosine (8-oxodG) and
8-oxo-7,8-dihydroguanosine (8-oxoGuo) are biomarkers of sys-
temic oxidative stress on DNA and RNA, respectively. Urinary
8-oxodG has been extensively validated as a marker of oxidatively
generated DNA damage through a number of studies (Deng et al.,
1998; Evans et al., 2010b; Loft et al., 1995) The experimental
induction of wide-spread DNA damage by an exogenous carcino-
gen lead to the transient accumulation of 8-oxodG in nuclear DNA
of the bone marrow, liver and kidneys, and a corresponding
increase in urinary 8-oxodG excretion in rats (Deng et al., 1998).
Circulating 8-oxodG is completely cleared through renal excre-
tion, and the urinary excretion of 8-oxodG thereby reﬂects the
overall whole-body oxidative stress on DNA (Evans et al., 2010b;
Loft et al., 1995). Although similar validation data on 8-oxoGuo
are not available, the two markers are usually closely correlated
(Joergensen et al., 2011), and thus probably reﬂect the same
whole-body oxidative stress on nucleic acids.
For this study, we determined the urinary excretion of
8-oxodG and 8-oxoGuo in forty medicated schizophrenia patients
and forty age- and sex-matched controls. We further correlated
baseline and 4-month follow-up 8-oxodG/8-oxoGuo excretion to
measures of perceived psychological stress and cortisol secretion,
which have previously been linked to telomere attrition and
nucleic acid oxidation (Epel et al., 2004; Joergensen et al., 2011).
The urinary content of 8-oxodG/8-oxoGuo was assayed by a
highly speciﬁc and sensitive mass spectrometric detection
(Henriksen et al., 2009). The method has been extensively
validated, including in a recent international, inter-laboratory
collaboration (Evans et al., 2010a).
We hypothesized an increased excretion of nucleic acid oxida-
tion markers in schizophrenia patients vs. controls, and a positive
correlation between perceived stress/cortisol secretion and the
marker excretion, both at baseline as well as in relation to
changes over a 4 month period.2. Methods
2.1. General study outline
Recruitment took place from September 2008 through May 2011. Patients
were recruited by referral from doctors at the Psychiatric Centre Copenhagen,
which provides mental health services to the citizens of the central, northern and
north-western area of Copenhagen. Physicians at the centre were informed of the
study in writing and by word of mouth, and received regular reminders to refer
patients. Both inpatients as well as patients from the afﬁliated outpatient clinics
were recruited. Investigations were carried out at baseline (‘‘T0’’) and repeated
after 4 months (‘‘T4’’). In the intermediate period, patients received treatment as
usual, including medication.
The inclusion criterion for patients was an ICD-10 diagnosis of either schizo-
phrenia or acute schizophreniform psychosis, conﬁrmed by a structured interviewat referral. Exclusion criteria were: (1) somatic disease and somatic medication. A
non-regular use of e.g. painkillers or asthma medication was allowed, (2) abuse of
alcohol, marihuana or other drugs of abuse, (3) coercion of any kind, (4) severely
disorganised thinking, making it impossible to obtain an informed consent, (5) use
of dietary supplements, and (6) pregnancy or breast-feeding. Of forty-ﬁve patients
referred to the study and accepting to participate, 40 were included. In the
rejected patients, the diagnosis of schizophrenia was considered uncertain after
the inclusion interview (N¼4), or the biochemical screening revealed a medical
disorder (N¼1).
Healthy controls were recruited from the blood donation corps at Rigshospita-
let by personal contact, as they were scheduled for donating blood. Exclusion
criteria for the healthy controls were: (1) any psychiatric or somatic disease,
(2) abuse of alcohol, marihuana or other drugs, (3) use of any medication including
dietary supplements, and (4) ﬁrst degree family members with psychiatric
disease. A total of 175 healthy controls meeting none of the exclusion criteria
were asked to participate, and of these, 40 accepted to be included. They
underwent the same examinations as the patients (except for schizophreniform
psychopathology), but were only examined at T0.
The study schedule was as follows: on day 1, blood was drawn in the fasting
state at 9 AM. In a few cases (two controls and six patients), blood was not drawn
in the morning, and these cases were omitted from analyses including plasma
cortisol. A spot urine sample was obtained from the ﬁrst voided urine after blood
sampling. Sociodemographic and clinical data were recorded. Ratings and ques-
tionnaires were completed. On day 2 (or no more than one week from the
examination), the participant made salivary samples for cortisol determination.
At T4, the sequence was repeated.
The study protocol complied with the Declaration of Helsinki, and was
approved by the Regional Commitee on Research Ethics (H-D-2008-064) and the
National Data Protection Agency (2008-41-2052). All participants gave a written
informed consent before inclusion.
2.2. Interviews and questionnaires
A Schedules in Clinical Neuropsychiatry (SCAN)-interview (Wing et al., 1990)
was applied at T0 to ensure that the ICD-10 diagnostic criteria for schizophrenia
(F20.0–F20.9) were met, and that no lifetime psychiatric morbidity was present in
the healthy controls. Medical doctors with previous clinical experience in
psychiatry performed all the SCAN ratings. The severity of psychopathology was
measured with the Positive and Negative Syndrome Scale (PANSS) (Kay et al.,
1987). Regular co-ratings with a certiﬁed expert PANSS-rater (AFJ) were per-
formed, yielding an Intraclass Correlation Coefﬁcient of 0.91 for positive items,
0.76 for negative items, 0.79 for general items and 0.83 for all items, indicating
very good agreement across all subscales. The level of perceived stress was
assessed with the Perceived Stress Scale 10-item (PSS) (Cohen and Williamson,
1988).
2.3. General biochemical screening
This comprised a full blood count, hepatic enzymes, total cholesterol, low-
density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, trigly-
cerides, C-reactive protein (CRP), thyroid stimulating hormone (TSH), sodium,
potassium, creatinine, glucose, glycated haemoglobin (HbA1c), and plasma
cortisol.
2.4. Urinary 8-oxodG and 8-oxoGuo
The urinary sample was obtained with a standard sampling kit without any
additives. Samples were kept on ice and transferred within hours to storage at
20 1C until analysis. The urinary content of the oxidatively modiﬁed guanine
nucleosides was assayed using ultraperformance liquid chromatography and
tandem mass spectrometry (UPLC–MS/MS). The chromatographic separation was
performed on an Acquity UPLC system (Waters, Milford, MA, USA). The column
used was an Acquity UPLC BEH Shield RP18 column (1.7 mm, 2.1100 mm2)
protected with in-line ﬁlter (42 mm2, 0.2 mm) both obtained from Waters. The
MS detection was performed on an API 3000 triple quadrupole mass spectrometer
(Sciex, Toronto, Canada) equipped with an ESI ion source (Turbospray) operated in
the positive mode. Details of the analysis are described elsewhere (Henriksen
et al., 2009). The urinary creatinine concentration was determined by Jaffe’s
reaction. The 8-oxodG/8-oxoGuo excretion is deﬁned as the urinary concentration
of the nucleoside normalised to urinary creatinine concentration (Evans et al.,
2010a).
2.5. Plasma markers
Plasma was obtained from EDTA-coated tubes which were centrifuged at 4 1C
and 1590 g for 10 min. Samples were stored at 80 1C within 30 min from
venipuncture. Malondialdehyde (MDA, a marker of lipid peroxidation), as well as
Table 1
Basic data of healthy controls and schizophrenia patients at baseline. Numbers are in mean (7 standard deviation)
or median (interquartile range).
Control (N¼40) Schizophrenia (N¼40) P-value
Gender (M/F) 20/20 20/20 1.0
Age (years) 31.4 (79.8) 33.0 (710.7) 0.49
Ethnicity (Caucasian/other) 40/0 37/3 0.21
Education (years)a 4 (3–5) 3 (0–3) 0.003
Smoker (%) 21 55 0.002
Cigarettes per day (if smoker) 8.1 (76.4) 18.1 (711.3) 0.03
Alcohol (drinks per week) 5 (2–10) 1 (0–5) 0.002
Exercise (hours per week) 3 (1–5) 0 (0–2) o0.001
Oral contraceptives (number of users) 1 5 o0.001
Body Mass Index 25.1 (73.8) 27.2 (75.7) 0.06
Waist–hip ratio 0.80 (70.07) 0.89 (70.08) o0.001
Systolic blood pressure (mmHg) 124.6 (711.6) 127.1 (712.2) 0.34
Diastolic blood pressure (mmHg) 78.9 (78.6) 78.5 (77.3) 0.37
Pulse (min1) 64.6 (710.6) 81.0 (714.3) o0.001
Total cholesterol (mmol/L) 4.7 (70.8) 4.9 (70.9) 0.44
HDL cholesterol (mmol/L) 1.5 (70.4) 1.4 (70.4) 0.40
LDL cholesterol (mmol/L) 2.8 (70.6) 2.8 (70.8) 0.75
Triglycerides (mmol/L) 0.90 (0.70–1.15) 1.25 (0.76–2.00) 0.02
Glucose (mmol/L) 5.2 (70.4) 5.1 (70.6) 0.48
HbA1c (mmol/L) 5.2 (70.3) 5.4 (70.4) 0.01
Plasma Creatinine (mmol/L) 73 (716) 69 (714) 0.20
Urine Creatinine (mmol/L) 12.3 (76.3) 13.9 (78.4) 0.34
CRP (mg/L) 1 (1–2) 2 (1–4) 0.002
TSH (103 IU/L) 1.65 (1.16–2.27) 1.80 (1.46–2.73) 0.04
Plasma cortisol (nmol/L) 442 (310–525) 494 (394–666) 0.03
Plasma vitamin C (mmol/L) 61.8 (714.1) 53.7 (723.6) 0.07
Plasma uric acid (mmol/L) 245 (752) 237 (756) 0.53
Data are analysed with t-test, Mann–Whitney test or Chi-squared test, as appropriate.
Abbreviations: HDL: high-density lipoprotein. LDL: low-density lipoprotein. HbA1c: glycated haemoglobin.
CRP: C-reactive protein. TSH: thyroid stimulating hormone.
a Years of completed education beyond Danish compulsory school (9 years).
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previously described chromatographic methods (Lykkesfeldt, 2001, 2007a).
2.6. Salivary cortisol
Samples were obtained by the ‘‘Salivette’’ system immediately upon awaken-
ing, at 15, 30, 45 and 60 min after awakening, at 6 PM and at 11 PM. Samples were
made either in the participant’s own home and mailed to the laboratory (controls
and out-patients) or at the ward (in-patients). Salivary cortisol is preserved for
weeks at room temperature (Kirschbaum and Hellhammer, 1994). Participants
were instructed to keep the Salivette cotton wad in the mouth for 41 min, and
were not allowed to eat, smoke, brush his teeth or drink (other than small
amounts of water) 30 min before each sample. Participants were given a form on
which they noted the time they fell to sleep the night before sampling, woke up on
the morning of the sampling and the time they made every sample. Upon receipt
at the laboratory, the Salivette tubes were centrifugated at 1590g for 5–10 min to
extract the saliva. Samples were stored at 80 1C until analysis.
Saliva was assayed for cortisol by an electrochemiluminescence immunoassay,
using a commercially available kit (Roche Diagnostics GmbH, Mannheim,
Germany). The lower detection limit of the assay was 1 nmol/L. The inter- and
intra-assay coefﬁcients of variation of the assay of were 7.1% and 4.0%, respec-
tively, according to the manufacturer. The area under the curve with respect to the
ground level for all samples (AUCg) were calculated for each participant by the
trapezoidal rule (Pruessner et al., 2003), which incorporates cortisol values and
the exact times between samples to estimate whole-day ‘‘exposure’’ to unbound
cortisol. Before computations, extreme values in each group for each time point
(outside the 99th percentile) were excluded (30 out of a total of 658 determina-
tions). For series of samples with more than one sample missing, the AUC was not
computed. If only one sample was missing, values were replaced by the mean of
the two adjacent values, or, if the missing value were either the awakening or
11 PM sample, by the mean of the full sample for that time point. We were able
to compute AUCg for 31 controls and 29 patients at T0, and for 22 patients at T4.
In both groups, cortisol concentrations displayed the expected diurnal pattern
(peak values at 30 min after awakening and nadir at 11 PM).
All samples from each participant were analysed in the same batch, but
control and patient samples were analysed on separate occasions. Therefore, we
refrained from making direct comparisons between patients and controls, and
only analysed the correlations with 8-oxodG/8-oxoGuo in each group separately.2.7. Statistics
All data are presented as means (7 standard deviation) or median (inter-
quartile range). Normal distributed data were analysed with independent samples
t-tests, analysis of variance (ANOVA) or paired samples t-tests as relevant, and
non-normal distributed data with Mann–Whitney test. For categorial data,
Chi-squared tests were used. For the analysis of 8-oxodG/8-oxoGuo, Pearson
correlations and two multiple linear regression models were applied. In model 1,
the independent variables were demographical and lifestyle factors potentially
associated with oxidative stress (age, gender, ethnicity, smoking, alcohol intake,
exercise and oral contraceptive use). Model 2 additionally included as indepen-
dent variables all the clinical and metabolic factors showing differences between
the groups (waist–hip ratio, pulse, triglycerides, HbA1c, CRP, TSH and cortisol), as
well as the plasma antioxidants (Table 1). For all parametric tests, the dependent
variables in question deviating from normal distribution (8-oxodG/8-oxoGuo and
plasma cortisol) were transformed by the natural logarithm. All statistical
analyses were performed using the Statistical Package for the Social Sciences
(SPSS) software version 20.0 (IBM Corporation, NY, USA). Statistical signiﬁcance
was deﬁned as Po0.05. All statistical tests were two sided.3. Results
Basic data of patients and controls are presented in Table 1.
The urinary excretion of both 8-oxodG and 8-oxoGuo was
signiﬁcantly increased in the schizophrenia vs. the control group
(8-oxodG: 1.7 (1.4–2.4) vs. 1.4 (1.2–1.6) nmol/mmol urinary
creatinine, Mann–Whitney U-test, Mann–Whitney U (MWU)¼
496.0, P¼0.003. 8-oxoGuo: 2.2 (1.9–2.7) vs. 1.8 (1.4–2.1) nmol/
mmol, MWU¼348.0, Po0.001) (Fig. 1). The effect size (Cohen’s d)
was 0.69 for 8-oxodG and 1.13 for 8-oxoGuo, indicating a
moderate and large effect, respectively. The median excretion of
8-oxoGuo was 29% higher than 8-oxodG in both groups, and the
two markers were highly correlated (Pearson’s r¼0.52, Po0.001).
In contrast to the nucleic acid oxidation markers, MDA did not
Fig. 1. Urinary 8-oxodG (left) and 8-oxoGuo (right) excretion (nmol/mmol creatinin) in healthy controls and schizophrenia patients. nP¼0.003, Po0.001, Mann–Whitney test.
Table 2
Clinical characteristics of schizophrenia patients at baseline. Numbers are in mean







Age of onset (years) 23.0 (75.3)
Duration of illness (months) 76 (36–189)
Number of admissions 3 (1–6)
In-patient at inclusion 60%
Medicationa
Duration of current antipsychotic treatment (months) 20 (3–68)
Number of antipsychotics used
One 77%
Two or three 23%
Antipsychotics, Deﬁned Daily Doseb 1.5 (0.7–2.3)
Antidepressant use 43%
If antidepressant use, Deﬁned Daily Dose 1.4 (1.0–2.0)
Benzodiazepine use 28%
If benzodiazepine use, Deﬁned Daily Dose 0.6 (0.3–1.2)
Psychopathology
PANSS positive score 22.2 (74.3)
PANSS negative score 22.3 (75.6)
PANSS general score 44.6 (78.5)
PANSS total score 89.1 (716.5)
a All patients received second-generation antipsychotics. Apart from the listed
medications, three patients received anticholinergic agents, two patients received
antiepileptics and one patient received electroconvulsive therapy.
b As deﬁned by the World Health Organization.
A. Jorgensen et al. / Psychiatry Research 209 (2013) 417–423420signiﬁcantly differ between the groups (controls: 0.89 (70.23)
mmol/L, schizophrenia: 0.78 (70.33) mmol/L, independent sam-
ples t-test, t¼1.53, d.f.¼74, P¼0.13).
The difference in 8-oxodG/8-oxoGuo excretion between the
groups persisted after the adjustment for demographical and
lifestyle variables (Model 1) (8-oxodG: b¼0.52, Po0.001. 8-oxo-
Guo: b¼0.68, Po0.001). After the additional adjustment for
multiple clinical and metabolic factors (model 2), group was still
signiﬁcantly associated with 8-oxodG/8-oxoGuo excretion (8-
oxodG: b¼0.61, P¼0.002. 8-oxoGuo: b¼0.64, P¼0.002). In a
separate analysis, we found no difference in neither marker
between smokers vs. non-smokers in neither the control (8-
oxodG: MWU¼99.0, P¼0.33. 8-oxoGuo: MWU¼98.0, P¼0.31)
nor in the patient group (8-oxodG: MWU¼146.0, P¼0.16. 8-oxo-
Guo: MWU¼160.0, P¼0.3).
The clinical baseline characteristics of schizophrenia patients
are shown in Table 2. All patients received second generation
antipsychotics (SGA). The primary antipsychotic agent used was
risperidone (N¼9), quetiapine (N¼9), aripiprazole (N¼6), olanza-
pine (N¼5) or clozapine (N¼5). Six patients received other SGAs.
None of the markers showed associations with the number of
antipsychotics used (8-oxodG: one-way ANOVA, F(2,37)¼0.52,
P¼0.60, 8-oxoGuo: F(2,37)¼1.26, P¼0.30), the Deﬁned Daily Dose
(DDD) of antipsychotics (8-oxodG: Pearson’s r¼0.18, P¼0.26,
8-oxoGuo: r¼0.11, P¼0.5) or the total DDD of all medications
(8-oxodG: r¼0.26, P¼0.1, 8-oxoGuo: r¼0.06, P¼0.73). The
individual agents were not associated with signiﬁcant differences
in the marker excretion, except for a higher 8-oxodG excretion in
the ﬁve clozapine users compared to risperidone users (one-way
ANOVA, F(5,34)¼3.3, P¼0.02, post-hoc Tukey test of clozapine vs.
risperidone: P¼0.006). The 8-oxodG/8-oxoGuo excretion was
not associated with the duration of illness (even after adjusting
for age), number of admissions, or admission status (in- or
out-patient) at the time of inclusion.
As expected, patients had substantially higher perceived stress
scores than healthy controls (22.3 (76.7) vs. 7.7 (74.2) points,independent samples t-test, t¼12.1, d.f.¼78, Po0.001). There
were no signiﬁcant associations between PSS scores and the
nucleic acid oxidation markers in neither the control nor the
schizophrenia group. Neither the total nor any subscale PANSS scores
of schizophrenia patients correlated with either of the markers.
Fig. 2. Scatterplots of the relation between the excretion of 8-oxodG/8-oxoGuo (Ln-transformed values), 9 AM plasma cortisol (Ln-transformed values, AþB) and the AUC
for salivary cortisol (arbitrary units, CþD) in healthy controls (CON, upper panel) and schizophrenia patients (SCZ, lower panel). (A) 8-oxodG vs. 9 AM plasma cortisol.
CON: Pearson’s correlation coefﬁcient (r)¼0.46, P¼0.003; SCZ: r¼0.03, P¼0.87. (B) 8-oxoGuo vs. 9 AM plasma cortisol. CON: r¼0.46, P¼0.004; SCZ: r¼0.43, P¼0.02.
(C) 8-oxodG vs. the AUCg for salivary cortisol. CON: r¼0.10, P¼0.58; SCZ: r¼0.01, P¼0.62. (D) 8-oxoGuo vs. the AUCg for salivary cortisol. CON: r¼0.07, P¼0.71; SCZ:
r¼0.27, P¼0.16.
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with the log-transformed 9 AM plasma cortisol, while being non-
associated or signiﬁcantly negatively associated with the plasma
cortisol in the schizophrenia group. For the correlation to AUCg, a
similar pattern of a more negative slope in the schizophrenia
group was seen (results are summarized in Fig. 2). There were no
signiﬁcant correlations between plasma MDA and the cortisol
measures in neither group (data not shown).
Eighty per cent of the included patients completed the study at
T4. Of the non-completers, four refused to participate, two could
not be contacted, and two had developed somatic disease. There
were no signiﬁcant differences between the completers and the
non-completers with respect to age (independent samples t-test,
t¼1.12, d.f.¼38, P¼0.91), DDD of antipsychotic medication
(t¼0.7, d.f.¼38, P¼0.49), or total PANSS score (t¼0.45,
d.f.¼38, P¼0.65). DDDs of SGAs or all medications were not
changed from T0 to T4 (DDD, SGA: Wilcoxon Signed Ranks test,
Z¼0.2, P¼0.84. DDD, all medications: Z¼0.3, P¼0.77).
The T4 median excretion of 8-oxodG/8-oxoGuo continued to be
elevated in comparison to the T0 levels of healthy controls (8-oxodG:
Mann–Whitney U-test, MWU¼460.0, P¼0.04, 8-oxoGuo: MWU¼
347.0, P¼0.001), reﬂecting a strong intra-individual correlation
between T0 and T4 values (8-oxodG: Pearson’s r¼0.62, Po0.001.
8-oxoGuo: r¼0.58, P¼0.001). We found no associations between T0
and T4 changes in 8-oxodG/8-oxoGuo excretion vs. changes in PANSS
(range: 28–þ23 points), PSS, or cortisol secretion.4. Discussion
Only a few studies have examined levels of DNA damage in
schizophrenia. Two previous studies did not ﬁnd elevated lym-
phocyte DNA strand breaks, as measured by the comet assay,
compared to controls (Psimadas et al., 2004; Young et al., 2007).
A recent study found increased levels of phosphorylated histone
variant H2AX, an index of DNA double strand breaks, in culturedlymphoblasts from schizophrenia patients compared to healthy
controls, and an attenuated activation of the same marker after
cell irradiation in patients (Catts et al., 2012). In a post-mortem
study, an increased intra-neuronal 8-oxodG immunoreactivity in
the hippocampus of elderly, poor-outcome schizophrenia patients
was observed (Nishioka and Arnold, 2004). However, to our
knowledge, this study provides the ﬁrst evidence for increased
systemic DNA and RNA oxidation in vivo in schizophrenia. In our
cohort, the median urinary excretion of both 8-oxodG and
8-oxoGuo was approximately 20% higher in the schizophrenia
patients, and the difference persisted after the adjustment for
multiple confounders of oxidative stress, indicating that the
increased nucleic acid oxidation in patients is not merely an
epiphenomenon of lifestyle or dysmetabolism.
Although the data by no means proves a causal relationship
between schizophrenia and oxidatively generated DNA/RNA
damage, the ﬁnding is not inconsistent with the hypothesis that
oxidative stress is a pathophysiological mechanism in schizo-
phrenia. In contrast to the ﬁnding of others (Arvindakshan et al.,
2003b; Zhang et al., 2006), plasma markers of lipid peroxidation
and antioxidant status did not differ between the groups. This
discrepancy could be due to methodological issues, in that the
above-mentioned studies determined MDA by the Thiobarbituric
Acid assay, whereas we used HPLC, which is considered a more
speciﬁc method for the measurement of MDA (Lykkesfeldt,
2007b). Our ﬁnding could indicate a speciﬁc susceptibility to
nucleic acid oxidation in schizophrenia. The mitochondria are the
primary source of ROS, and disturbances of mitochondrial function
will lead to increased formation of ROS and oxidative stress (Turrens,
2003). If mitochondrial perturbations are a core feature of the biology
of schizophrenia as suggested by others (Jablensky et al., 2012;
Prabakaran et al., 2004; Rosenfeld et al., 2011), thenmolecules located
in the proximity of the mitochondria, such as RNA and mitochondrial
DNA, could be speculated to be particularly exposed to oxidative
damage, whereas markers of extracellular oxidative processes such as
plasma MDA would be relatively unaffected.
A. Jorgensen et al. / Psychiatry Research 209 (2013) 417–423422The markers remained elevated at a 4-month follow-up
examination in the patients, reﬂecting a strong correlation
between intra-individual T0 and T4 values, and were not corre-
lated to the duration of illness or any measure of current severity
of disease. This indicates that the elevated nucleic acid damage
from oxidation is a ‘‘trait’’ rather than a ‘‘state’’ phenomenon,
possibly due to a genetically determined increased oxidative
stress, as suggested by others (Tosic et al., 2006), or as a result
of more persistent and stable metabolic changes developing early
in the disease course.
Our ﬁnding could have implications for the signs of acceler-
ated aging observed in schizophrenia. Genotoxic stress caused by
oxidants is recognised as a critical event in cellular aging (Finkel
and Holbrook, 2000). The oxidatively generated damage to DNA
accumulates with age and may induce cell senescence or apop-
tosis (Moller et al., 2010; Sahin and DePinho, 2010). Furthermore,
an increasing attention to RNA oxidation as an instigator of
human aging and neuropathology is emerging (Nunomura et al.,
2009). Interestingly, a recent post-mortem study found increased
oxidation of RNA, but not of DNA, in the hippocampus of
schizophrenia patients (Che et al., 2010). Similarly, we found a
more pronounced difference in the RNA marker excretion (effect
size (Cohen’s d)¼1.13) compared to the DNA marker excretion
(Cohen’s d¼0.69) in patients vs. controls.
The UPLC–MS/MS method for the detection of urinary nucleo-
sides has been extensively validated and allows for a high
throughput analysis of samples obtained non-invasively (Evans
et al., 2010a), and the determined excretion levels of 8-oxodG/
8-oxoGuo are within the reference ranges reported by others
(Andreoli et al., 2011). Based on this, 8-oxodG/8-oxoGuo could
have utility as biomarkers in larger-scale, prospective studies of
aging and mortality in schizophrenia. As an illustration of this
potential use, we recently found 8-oxoGuo (but not 8-oxodG) to
be an independent predictor of long-term mortality in a large
cohort of newly diagnosed type II diabetics (Broedbaek et al.,
2011).
We did not ﬁnd the expected association between the marker
excretion and measures of cortisol secretion in schizophrenia
patients. In contrast, and in replication of a previous ﬁnding
(Joergensen et al., 2011), plasma cortisol were positively corre-
lated to both markers in the control group. Corticosteroids impact
on mitochondrial function (Du et al., 2009) and tissue DNA
oxidation levels (Caro et al., 2007). The lack of an association –
or even a negative association – in the schizophrenia patients
suggests that the cause of the increased nucleic acid oxidation lies
outside of the neurohormonal stress response. It could be specu-
lated that the chronic stress state of suffering from schizophrenia
leads to a reduced cellular sensitivity to cortisol, as previously
found in a non-pathological human stress condition (being
caregiver for a cancer patient) (Miller et al., 2008).
There are several limitations to the study. (1) The cross-
sectional comparison of patients and controls does not allow for
inferences on the mechanistic relationship between schizophre-
nia and oxidatively generated nucleic acid damage, and confound-
ing factors which were not determined in the study could
contribute to the ﬁnding. (2) The sample size is relatively low,
and this may explain the null ﬁnding with regards to the
association between 8-oxodG/8-oxoGuo and the psychometric
variables (psychopathology and perceived stress). (3) We found
no associations between the markers and any measure of medica-
tion load, and this is in line with evidence that only the ﬁrst
generation antipsychotics induce oxidative stress (Kropp et al.,
2005). However, an effect of medication cannot entirely be ruled
out, and the ﬁnding should be replicated in drug-naı¨ve patients.
(4) Likewise, while we found no effect of smoking on the markers
in neither group, and the adjustment for smoking in multipleregression analysis did not alter the result, we can not rule out an
effect of smoking habits, which differed substantially between the
patient and control groups.
In conclusion, we found that schizophrenia was associated
with a 20% increase in median urinary excretion of DNA and RNA
oxidation markers compared to healthy controls. This difference
remained signiﬁcant after the adjustment for multiple socio-
demographic, lifestyle, and metabolic variables. Although causal
relations cannot be inferred from the study, increased rates of
oxidatively generated nucleic acid damage could constitute a
molecular link between schizophrenia and the signs of acceler-
ated aging associated with this severe mental disorder.Acknowledgements
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